Moreover, the 36-month beta value for CYCC is 0.51. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for CYCC is 12.71M and currently, short sellers hold a 0.22% of that float. On April 29, 2025, CYCC’s average trading volume was 345.49K shares.
CYCC) stock’s latest price update
The stock of Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) has increased by 2.44 when compared to last closing price of 0.28. Despite this, the company has experienced a 35.15% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-04-02 that BERKELEY HEIGHTS, N.J., April 02, 2025 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines, today announced fourth quarter financial results and provided a business update.
CYCC’s Market Performance
Cyclacel Pharmaceuticals Inc (CYCC) has experienced a 35.15% rise in stock performance for the past week, with a -6.70% drop in the past month, and a -24.92% drop in the past quarter. The volatility ratio for the week is 25.28%, and the volatility levels for the past 30 days are at 15.37% for CYCC. The simple moving average for the last 20 days is 21.89% for CYCC stock, with a simple moving average of -58.21% for the last 200 days.
Analysts’ Opinion of CYCC
Many brokerage firms have already submitted their reports for CYCC stocks, with Oppenheimer repeating the rating for CYCC by listing it as a “Outperform.” The predicted price for CYCC in the upcoming period, according to Oppenheimer is $17 based on the research report published on July 18, 2022 of the previous year 2022.
ROTH Capital, on the other hand, stated in their research note that they expect to see CYCC reach a price target of $24. The rating they have provided for CYCC stocks is “Buy” according to the report published on April 27th, 2020.
CYCC Trading at -0.52% from the 50-Day Moving Average
After a stumble in the market that brought CYCC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -92.87% of loss for the given period.
Volatility was left at 15.37%, however, over the last 30 days, the volatility rate increased by 25.28%, as shares sank -4.58% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -13.02% lower at present.
During the last 5 trading sessions, CYCC rose by +35.15%, which changed the moving average for the period of 200-days by -82.06% in comparison to the 20-day moving average, which settled at $0.2341. In addition, Cyclacel Pharmaceuticals Inc saw -24.12% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CYCC starting from Lazar David E., who sale 194,628,820 shares at the price of $0.03 back on Feb 26 ’25. After this action, Lazar David E. now owns 0 shares of Cyclacel Pharmaceuticals Inc, valued at $5,507,996 using the latest closing price.
Stock Fundamentals for CYCC
Current profitability levels for the company are sitting at:
- -347.19 for the present operating margin
- 0.91 for the gross margin
The net margin for Cyclacel Pharmaceuticals Inc stands at -215.28. The total capital return value is set at 6.87. Equity return is now at value -807.39, with -173.81 for asset returns.
Currently, EBITDA for the company is -12.0 million with net debt to EBITDA at 0.26. When we switch over and look at the enterprise to sales, we see a ratio of 1302.7. The receivables turnover for the company is 0.18for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.59.
Conclusion
To wrap up, the performance of Cyclacel Pharmaceuticals Inc (CYCC) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
